Translational Drug Development (TD2)
Marc Appelbaum's work experience includes being the Vice President of Sales at Translational Drug Development (TD2) since 2014. In this role, they manage and directs the sales and marketing efforts to assist clients in achieving milestones for their oncology compound development. Prior to that, they worked as a Senior Account Executive at Covance from 2008 to 2014. Before Covance, they were a District Manager at Abbott Diagnostics from 1999 to 2008 and a Sales Representative at Nystrom from 1992 to 1997.
Marc Appelbaum received their Bachelor of Science degree in Psychology from the State University of New York at Oswego, where they studied from 1986 to 1990. Marc then went on to earn their Master of Science degree in Education from Alfred University between 1988 and 1990.
This person is not in any offices
Translational Drug Development (TD2)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.